<span>Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection</span>
May 18, 2022

Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection

BURLINGTON, N.C. --(BUSINESS WIRE)--May 18, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.